2results about How to "Inhibition level" patented technology

This invention discloses the application of a Trichinella spiralis cysteine ​​protease inhibitor in acute myocardial infarction and subsequent ventricular remodeling, belonging to the field of medicinal chemistry. This invention provides a drug that can prevent, alleviate, and / or treat acute myocardial infarction and subsequent ventricular remodeling. The active ingredient of this drug is the Trichinella spiralis cysteine ​​protease inhibitor cystatin, abbreviated as rTs-Cys. rTs-Cys can effectively delay acute myocardial infarction and inflammatory response in mice, reduce the infarct area, improve cardiac function deterioration, and reverse organ pathological damage, providing a new approach for the clinical treatment of acute myocardial infarction and subsequent ventricular remodeling.

This invention relates to the field of biomedical technology, and more particularly to the application of an isoflavone compound, specifically Corylifol A, in the preparation of drugs for the prevention and / or treatment of inflammatory diseases. When used to prepare drugs for the prevention and / or treatment of inflammatory diseases, this isoflavone compound can directly bind to the IκBα protein and specifically inhibit its phosphorylation, thereby blocking the phosphorylation and nuclear translocation of the NF-κB p65 subunit, ultimately inhibiting the overactivation of the NF-κB signaling pathway. Furthermore, the isoflavone compound can significantly reduce the mortality rate of lipopolysaccharide-induced septicemia in mice, inhibit the levels of inflammatory factors in serum and lung tissue, and effectively alleviate LPS-induced acute lung injury in mice. Simultaneously, when the isoflavone compound is controlled within an effective concentration range, it exhibits no significant cytotoxicity to mouse peritoneal macrophages and can significantly inhibit the production and release of lipopolysaccharide-induced inflammatory factors IL-1β, TNF-α, and IL-6.